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We have established a refined methodology for generating surface plasmon
resonance sensor surfaces of recombinant his-tagged human cyclophilin-A.
Our orientation-specific stabilisation approach captures his-tagged protein
under ‘physiological conditions’ (150 mM NaCl, pH 7.5) and covalently sta-
bilises it on Ni2+-nitrilotriacetic acid surfaces, very briefly activated for pri-
mary amine-coupling reactions, producing very stable and active surfaces
(≥ 95% specific activity) of cyclophilin-A. Variation in protein concentra-
tion with the same contact time allows straightforward generation of vari-
able density surfaces, with essentially no loss of activity, making the
protocol easily adaptable for studying numerous interactions; from very
small fragments, ~ 100 Da, to large protein ligands. This new method
results in an increased stability and activity of the immobilised protein and
allowed us to expand the thermo-kinetic analysis space, and to determine
accurate and robust thermodynamic parameters for the cyclophilin-
A–cyclosporin-A interaction. Furthermore, the increased sensitivity of the
surface allowed identification of a new nonpeptide inhibitor of cyclophilin-
A, from a screen of a fragment library. This fragment, 2,3-diaminopyri-
dine, bound specifically with a mean affinity of 248  60 lM. The X-ray
structure of this 109-Da fragment bound in the active site of cyclophilin-A
was solved to a resolution of 1.25 A (PDB: 5LUD), providing new insight
into the molecular details for a potential new series of nonpeptide cyclophi-
lin-A inhibitors.
Over the course of the last decade surface plasmon res-
onance (SPR) systems, along with their control and
analysis software, have become easier and simpler to
operate, to such an extent that they are almost univer-
sally available in laboratories for the characterisation
of biomolecular interactions and small molecule drug-
discovery/hit validation studies [1–9]. The major
advantage of SPR instrumentation is that it allows the
measurement of kinetic and affinity parameters and
derivation of thermodynamic data specifically associ-
ated with complex formation and dissociation. Such
thermodynamic profiling [10–12] can greatly enhance
the correlation of solution-binding measurements with
structural features. This, in turn, allows the assignment
of proportional energetic contributions to individual
functional groups involved in the formation of a
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complex; the whole basis of structure-based
approaches to engineered therapeutics and drug design
[9,13–15]. The ready availability and ease of use of the
technology has to be tempered with a vigorous
approach to validation of the surface being studied,
especially for nonexperts. It is comparatively straight-
forward to produce an ‘active’ sensor surface that dis-
plays a ‘binding response’. However, in many SPR
studies the experimental design lacks appropriate opti-
misation, and the data generated often inappropriately
interpreted and/or analysed [16–19]. This unfortunately
leads to the derivation of affinity and kinetic parame-
ters that are not physiologically appropriate to the
protein/system being studied, and poor correlation
with the literature data from alternative approaches.
We have developed a simple and refined methodol-
ogy for generating highly stable and active SPR sensor
surfaces of recombinant human his-tagged cyclophilin-
A (His-CypA). Surfaces created by this approach
produce values for the kinetic, equilibrium and ther-
modynamic parameters for the binary cyclophilin-A–
cyclosporin-A (CsA) complex that correlates extremely
well with data determined by a multitude of other
solution techniques [20–30]. Cyclophilins are a large
subfamily of isomerases that catalyse the conversion of
prolyl-cis/trans isomers in folding polypeptide chains
[Peptidyl prolyl isomerase (PPIases), EC 5.2.1.8]. The
most extensively studied member of the family is the
cytoplasmic isoform CypA and its natural, low-nano-
molar affinity, immunosuppressive cyclic undecapep-
tide inhibitor CsA [31]. As well as playing roles in
protein folding, CypA appears to be a fundamental
component in numerous, quite disparate, biological
processes [32] including viral infections [33–41],
responses to inflammation [42] and a growing number
of proliferative cancers and malignancies [43–45]. This
has resulted in considerable interest in the development
of nonimmunosuppressive, nonpeptide CypA inhibi-
tors as mechanistic tools and potential drugs for vari-
ous diseases.
Although the basic framework of the methodology
described in this article is grounded on initial work
developed in our lab, the new protocols have been
very significantly, and rationally, optimised. Our orien-
tation-specific stabilisation approach captures his-
tagged proteins under ‘physiological conditions’
(150 mM NaCl, pH 7.5) on Ni2+-charged nitrilotri-
acetic acid surfaces, which have been very briefly acti-
vated for primary amine-coupling reactions. This
produces very stable and active surfaces of His-CypA.
Simple alteration of protein concentration with the
same contact time (30 s) allows variable density sur-
faces to be easily made, with no loss of specific
activity. Surfaces can thus be easily tailored for the
study of numerous interactions; ranging from very
small fragments (~ 100 Da) through to large protein
ligands. The streamlined procedure increased the sta-
bility and activity of the protein on the sensor surfaces
and allowed us to greatly expand the thermo-kinetic
analysis space; from 5 °C to 44 °C. We subsequently
generated much more detailed and robust sets of
kinetic and thermodynamic parameters for the CypA–
CsA interaction and identified and characterised a
small fragment, 2,3-diaminopyridine (Mw = 109 Da)
that bound stoichiometrically to the active site of His-
CypA with a mean Kd of 248  60 lM. The X-ray
structure of this fragment bound in the active site of
CypA was also solved to a resolution of 1.25 A [Pro-
tein Data Bank (PDB): 5LUD], providing new insight
into the molecular details for potential development of
a new series of nonpeptide CypA inhibitors.
Materials and methods
Materials
All chemicals used were of the highest grade available com-
mercially.
Plasmid construction, protein production and
purification
The open reading frame encoding for full-length human
CypA (M1 – E165) was synthesised and codon optimised
(GENEART) for expression in Escherichia coli, with a
hexa-his tag (underlined), linker and a TEV protease
cleavage site (bold, underlined) fused to the N ter
minus (MSKYHHHHHHDYDIPTTENLYFQ/G-M1-Cyp
A). Standard GATEWAY methodology was used to gen-
erate an expression vector in pDESTTM14 (ThermoFisher,
Waltham, MA, USA). Recombinant protein was overex-
pressed and purified to homogeneity from OverExpress
C41 BL21(DE3) E. coli (Lucigen, Middleton, WI, USA),
grown shaking (260 r.p.m.) at 30 °C for 16 h in 50 mL of
EnPresso media (BioSilta, St. Ives, Cambridgeshire, UK)
containing carbenicillin (100 lgmL1). Cell pellets were
resuspended in 20 mM NaH2PO4, pH 7.4; 500 mM NaCl;
20 mM imidazole; plus protease inhibitors at 10% w/v, and
lysed at 6 °C by a single passage through a Constant Sys-
tems Cell Disruptor (1.1 kW TS Benchtop) set at 22 kpsi,
followed by centrifugation at 50 000 g for 1 h at 4 °C. The
supernatant was filtered (0.22 lm) and then subsequently
loaded onto an €AKTAXpressTM (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) system fitted with 5 mL
HiTrap Ni2+-IMAC FF (GE Healthcare) and HiPrep S200
26/60 HR (GE Healthcare) columns, with standard configu-
ration and settings for a two-step affinity-gel-filtration
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protocol. A single 10-column volume step to 100% IMAC
Elution buffer was used for elution from the IMAC col-
umn. Buffers used for the purification were; IMAC Load-
ing buffer: 20 mM NaH2PO4, pH 7.4; 500 mM NaCl;
20 mM Imidazole; 100 lM PMSF. IMAC Elution buffer:
20 mM NaH2PO4, pH 7.4; 500 mM NaCl; 500 mM Imida-
zole. Gel-Filtration Buffer: 10 mM NaH2PO4, pH 7.5;
150 mM NaCl; 50 lM EDTA. His-CypA was concentrated
to 100 lM and stored at 4 °C in Gel-Filtration Buffer or
processed for X-ray crystallography (see below). The stan-
dard culture and purification conditions described above
result in a final yield of 19.8 mg, per litre equivalent, of
≥ 95% pure (judged by SDS/PAGE) His-CypA.
Monodispersity and size analysis
Size-exclusion chromatography (€AKTAMicroTM; GE
Healthcare) coupled with UV, static light scattering and
refractive index (RI) detection (Viscotec SEC-MALS 20
and Viscotek RI Detector VE3580; Malvern Instruments,
Malvern, Worcestershire, UK) were used to determine the
absolute molecular mass of His-CypA in solution. Multiple
injections of 100 lL of 1 mgmL1 (47.5 lM) His-CypA
were run on a calibrated Superdex-75 10/300 GL (GE
Healthcare) size exclusion column pre-equilibrated in
10 mM NaH2PO4, pH 7.5; 150 mM NaCl; 50 lM EDTA at
22 °C with a flow rate of 0.8 mLmin1. Light scattering,
RI and A280 nm were analysed by a homo-polymer model
(OMNISEC software, v5.02; Malvern Instruments) using the
following parameters for His-CypA: @A280 nm/@
c = 0.71 AUmL1mg1, @n/@c = 0.185 mLg1 and buffer
RI value of 1.334. Mass distribution analysis of the pure
His-CypA protein solutions by dynamic light scattering
(DLS) was performed on a Zetasizer APS (Malvern Instru-
ments) with five repeat runs of 60 lL (1 mgmL1) in
10 mM NaH2PO4, pH 7.5; 150 mM NaCl; 50 lM EDTA, at
22 °C, with a 120-s equilibration.
Peptidyl prolyl isomerase assay
This assay determines the rate of the cis to trans conversion
of the peptidyl-prolyl amide bond in the substrate N-succi-
nyl-Ala-Ala-Pro-Phe-p-nitroanilide (AAPF-pNA). Selective
hydrolysis of AAtransPF-pNA by a-chymotrypsin releases
p-ntitroaniline, the accumulation of which is monitored by
absorbance at 400 nm. AAPF-pNA, in 470 mM LiCl; 2,2,
2-trifluroethanol at 200 mM, was diluted to 4 mM in the
same buffer immediately before use. Reactions were con-
ducted at 12 °C on a Jasco V550 spectrophotometer with
temperature control, in 50 mM HEPES, pH 8.0; 100 mM
NaCl; 0.5 mM DTT, in a total volume of 1 mL, essentially
as described [26,28] with minor modifications. The final
concentration of His-CypA and AAPF-pNA were 12.3 nM
and 100 lM respectively. The apparent equilibrium
dissociation constant, Kiapp, for the inhibitor was deter-
mined by a least squares fit of Eqn (1) to plots of the initial
reaction rate (background thermal isomerisation rate sub-
tracted), V0 (in lMs
1) versus the concentration of CsA in
nM.
V0 ¼ Vi=2 ½hCypA  fð½hCypA  ½CsA  KiappÞ
þ
ﬃﬃ
ð
p
ð½hCypA  ½CsA  KiappÞ2 þ ð4 ½hCypA
 KiappÞÞg: ð1Þ
where Vi is the reaction rate at zero inhibitor concentra-
tion, [CsA] is the concentration of added CsA, Kiapp is the
apparent equilibrium dissociation constant of CsA and
[hCypA] is the concentration of His-CypA. Correction for
competition with sAAcisPF-pNA substrate was performed
using Eqn (2).
Kd ¼ Kiapp
1þ ð½Sub=KmÞ ; ð2Þ
where [Sub] is the initial AAcisPF-pNA concentration
(mean concentration = 54.7  2.9 lM, SE, n = 9) and Km
is the Michealis constant of the substrate. For His-CypA,
the mean (SE, n = 9) Km, kcat and kcat/Km values are
703  72 lM, 6134  233 s1 and 8.06 9 106 M1s1
respectively.
Surface plasmon resonance equipment and
reagents
Surface plasmon resonance measurements were performed
using a BIAcore T200 instrument (GE Healthcare).
Ni2+-nitrilotriacetic acid and CM5 sensor chips, 1-ethyl-3-
(3-diaminopropyl) carbodiimide hydrochloride (EDC),
N-hydroxysuccinimide (NHS) and ethanolamine (H2N
(CH2)2OH) were purchased from GE Healthcare.
Optimised capture/stabilisation of His-CypA
Pure His-CypA was immobilised and covalently stabilised
on an nitrilotriacetic acid sensor chip using a refined proto-
col to that initially described [25]. Following Ni2+ priming
(30 s injection of 500 lM NiCl2 at 5 lLmin1), dextran
surface carboxylate groups were minimally activated by an
injection of 0.2 M EDC; 50 mM NHS at 5 lLmin1 for
between 30 and 420 s. His-CypA (at concentrations
between 10 and 400 nM), in 10 mM NaH2PO4, pH 7.5;
150 mM NaCl; 50 lM EDTA was captured via the hexa-his
tag and simultaneously covalently stabilised on the surface
by injection for 30 s, at 30 lLmin1. Immediately follow-
ing the capture/stabilisation step a single 15-s injection of
350 mM EDTA and 50 mM Imidazole in 10 mM NaH2PO4,
pH 7.5; 150 mM NaCl; 0.05% surfactant P20, 1% ethanol,
at 30 lLmin1 was used to remove noncovalently bound
protein, followed by a 180-s injection of 1 M H2N
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(CH2)2OH, pH 8.5 at 5 lLmin1. The surface was further
conditioned with a 600-s wash with 10 mM NaH2PO4, pH
7.5; 150 mM NaCl; 0.05% surfactant P20, 1% ethanol;
1 mM EDTA at 100 lLmin1. Specific protein activity was
assayed by passing saturating amounts of CsA (1.0 lM) in
10 mM NaH2PO4, pH 7.5, 150 mM NaCl, 50 lM EDTA;
0.05% surfactant P20; 1% ethanol over the surface and
was invariably greater than 95% for all densities generated.
Direct covalent immobilisation of His-CypA
His-CypA was immobilised on a CM5 sensor chip utilising
standard amine-coupling chemistry. The sensor chip surface
was activated by an injection of 0.2 M EDC; 50 mM NHS at
5 lLmin1 for 420 s. His-CypA (theoretical pI = 6.54) at
100 lgmL1 in 10 mM acetate, pH 5.8, and injected over the
activated surface for 30 s. The amount of His-CypA immo-
bilised on the activated surface was typically between 580
and 800 response units (RU). After the immobilisation of
the protein, a 420-s injection at 5 lLmin1, of 1 M H2N
(CH2)2OH, pH 8.5, was used to quench excess active succin-
imide ester groups. The surface was further conditioned with
a 600-s wash with 10 mM NaH2PO4, pH 7.5; 150 mM NaCl;
0.05% surfactant P20, 1% ethanol at 100 lLmin1.
SPR thermodynamic experiments
The SPR single cycle kinetic experiments with CsA were
performed, in triplicate at temperatures from 5 °C to
44 °C, in 3 °C increments. A threefold concentration series
of CsA ranging from 2.47 to 200 nM, in 10 mM NaH2PO4,
pH 7.5, 150 mM NaCl, 1 mM EDTA; 0.05% surfactant
P20; 1% ethanol, was injected over the sensor surface, at
100 lLmin1 with 60 s contact and dissociation times. The
sensor surface was regenerated between experiments by dis-
sociating any formed complex in running buffer for 1800 s
at 100 lLmin1. The apparent on-rate, off-rate and equi-
librium dissociation constants were calculated from the sen-
sorgrams by global fitting of a 1 : 1 binding model, with
mass transport considerations, using analysis software
(v2.02) provided with the Biacore T200 instrument (GE
Healthcare).
Thermodynamic calculations
For equilibrium thermodynamics, the van’t Hoff equa-
tion states:
lnKd ¼ ðDH=RTÞ  ðDS=RÞ; ð3Þ
where Kd is the equilibrium dissociation constant, R is the
universal gas constant, T is the absolute temperature (K),
DH° is the standard enthalpy change and DS° is the stan-
dard entropy change. Plots of lnKd versus 1/T should be a
straight line, with a slope of DH°/R and an intercept on the
ordinate of DS°/R. However, this simplified relationship
will not hold if the heat capacities of the reactants differs
from the heat capacity of the complex and the relationship
between lnKd versus 1/T becomes
RT lnKd ¼ DHT  TDST þ DCpðT T0Þ
 TDCp lnðT=T0Þ; ð4Þ
where DCp° is the heat capacity change under standard
conditions, and T0 is the reference temperature (298 K)
[46]. Data were fitted using KALEIDAGRAPH v4.1.3 software
(Synergy Software, Reading, PA, USA).
Fragment library and compound screening
The Scottish Hit Discovery Facility fragment library (670
bioactive fragments) was obtained from the University of
Dundee Drug Discovery unit. Compounds were initially
screened at 1 mM on a surface of 2866 RU of His-CypA
(flowcell-2) and ~ 10 000 RU of covalently immobilised
(using standard amine chemistry) human serum albumin
(HSA; flowcell-4) in 10 mM NaH2PO4, pH 7.5; 150 mM
NaCl; 50 lM EDTA; 0.05% surfactant P20; 1% DMSO, at
30 lLmin1 with a contact time of 30 s and dissociation
time of 120 s. Solvent correction, carry-over assessment
and a 25% DMSO wash between samples were performed
as standard. Cyclophilin-A-specific hits were further anal-
ysed with a twofold concentration series from 0.0625 to
1 mM in 10 mM NaH2PO4, pH 7.5; 150 mM NaCl; 50 lM
EDTA; 0.05% surfactant P20; 1% DMSO, at 30 lLmin1
with a 30-s contact and dissociation time.
Crystallisation and X-ray crystallography
The His-tag was removed from CypA by His-TEV protease
(1 : 100 ratio, TEV : His-CypA with a 2-h incubation per-
iod at 30 °C) and the protein repurified as above to remove
free His-tag, His-TEV protease and any remaining
uncleaved His-CypA. Protein was concentrated to
25 mgmL1 in Gel-filtration Buffer (see above), minus
EDTA, and crystals were grown by vapour diffusion using
the hanging-drop method. CypA protein solution was
mixed 1 : 1 with 100 mM Tris, pH 8.0; 22% PEG 8000 and
crystals were obtained after 1 day at 4 °C. CypA:2,3-diami-
nopyridine complex was prepared by transferring a cover-
slip containing a drop of native CypA crystals over a well
solution of 35% PEG 8000 and equilibrating at 4 °C for
24 h. Following this, a single CypA crystal was transferred
into a 1 lL drop of 100 mM Tris, pH 8.0; 35% PEG 8000;
100 mM 2,3-diaminopyridine, and allowed to soak for 60 s.
The crystal (~ 0.2 mm in length) was then immediately
mounted in a 0.2-mm cryo-loop (Hampton Research, Aliso
Viejo, CA, USA) and flash cooled in liquid nitrogen, with
soaking solution acting as cryoprotectant. All diffraction
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data were collected at 100 K at the Diamond Light Source
(DLS), on station I02. Data processing was carried out
using MOSFLM [47] and AIMLESS [48]. The isomorphous
structure of cyclophilin-A in complex with the dipeptide
Gly-Pro (PDB ID 4N1M) was used to solve the structure
using the program REFMAC, [49] part of the CCP4 [50] suite
of programs. Refinement and model building were per-
formed using the program COOT [51].
Data accessibility
Atomic coordinates have been deposited in the Brookhaven
Protein Data Bank under the accession number PDB:
5LUD.
Miscellaneous
The molecular weights of CsA, His-CypA and 2,3-diamino-
pyridine are 1202.12, 21 040 and 109 Da respectively. Pro-
tein concentration was determined by A280 measurement
and the extinction coefficient 14 690 M1cm1.
Results and Discussion
One of the key criteria for successful SPR experiments
is having access to very pure, monodisperse, active
and stable protein. Our lab has previously generated
protocols for the production and purification of
numerous cyclophilins with very high purity and speci-
fic activity, both as tagged and untagged reagents,
from bacterial sources [22,26]. We have streamlined a
protocol for His-CypA purification (see Material and
methods) and Fig. 1 shows the typical high purity
(≥ 95%), monodispersity and activity of the protein
used in all our experiments. Size-exclusion chromatog-
raphy multiangle light scattering (SEC-MALS) analy-
sis was used to determine the molecular mass and
monodispersity of purified His-CypA in solution. On a
Superdex-75 10/300 GL (GE Healthcare) size-exclu-
sion column, His-CypA protein elutes a single sharp
and symmetrical peak with a correlative Rs of
1.82  0.11 nm (Fig. 1B). The molar mass average
across the elution profile is 19.8  0.4 kDa with excel-
lent monodispersity (Mw/Mn = 1.003). This is in
excellent agreement with theoretical molecular weight
of 21.04 kDa for monomeric His-CypA. DLS (data
not shown) analysis also indicates high monodispersity
for His-CypA solutions with a mean Rh of
1.85  0.17 nm (mean  SEM, n = 5), a polydisper-
sity index of ≤ 0.1 and a correlative molecular weight
of between 19 and 21 kDa, consistent with a highly
pure and monomeric protein solution. This protein is
also highly enzymatically active; Fig. 1C shows the
typical inhibition of His-CypA’s PPIase activity by
CsA. The mean kcat value of 6134  233 s1 and the
Ki value for CsA of 15.03  1.38 nM (SEM, n = 9)
are again consistent with coherent protein with a very
high specific activity [26,28].
Covalent immobilisation of proteins via primary
amine coupling is regularly the method of choice for
generating SPR sensor surfaces with no baseline drift.
It is a rapid and well-established process and simple to
implement. However, a significant proportion of pro-
teins are incompatible with such covalent coupling
strategies and as a consequence have aberrant or low
binding activity, or are even completely inactive, upon
immobilisation. This is certainly the case for the
human cyclophilins, especially CypA, in our hands
[26,52]. Alternative noncovalent capture methodologies
like the His-tag–Ni2+-nitrilotriacetic acid interaction,
are robust and allow for repeated immobilisation,
stripping and regeneration of the surface [53]. Never-
theless, these surfaces can often have low binding
capacities, and/or exhibit a slow and continuous disso-
ciation of the immobilised protein from the surface
[26,52,53]. Such a baseline drift, particularly prevalent
with high protein immobilisation levels (due to loss of
rebinding events) regularly required for small molecule
work, can create problematic assessment of the bind-
ing kinetics. Previous work from our lab had investi-
gated various orientation-specific capture/stabilisation
methods for the immunophilins, human CypA [25,26]
and human FK506-binding protein (FKBP12) [52] that
could not be actively immobilised by standard meth-
ods. Here, we report on the development of a simple
and streamlined methodology for His-CypA, that
allows creation of very stable (in excess of 500 individ-
ual cycles without significant decay in saturating ligand
concentration responses) and active SPR sensor sur-
faces (typically in excess of 95% specific activity). The
approach captures and orients His-tagged protein
under ‘physiological’ ionic and pH conditions (min-
imising or eliminating any spurious electrostatic
adsorption to the dextran matrix) on nitrilotriacetic
acid surfaces previously charged with Ni2 and mini-
mally activated for primary amine-coupling reactions,
prior to protein contact.
We first determined the length of time the sensor
surfaces were activated prior to his-tagged protein cap-
ture was important for not only the final level of pro-
tein immobilisation but also critically the specific
activity of the captured/stabilised molecules. The opti-
mal time for EDC:NHS activation of the precharged
Ni2+-nitrilotriacetic acid sensor surface was invariably
between 150 and 240 s, regardless of the concentration
of protein used (Fig. 2A). Less than 150 s of
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activation time resulted in low and more variable levels
of stabilised protein on the surface (Fig. 2A). Activat-
ing for longer than 240 s resulted in the specific activ-
ity dropping markedly below 80% (Fig. 2A) and the
resultant binding parameters measured using such sur-
faces for the CypA–CsA interaction deviate markedly
from accepted values for these constants. In our
hands, neither the kinetics of binding, nor the specific
activity of the surface, were affected to any significant
extent by the amount of protein immobilised on the
surface. Simply changing the concentration of
His-CypA from 10 to 400 nM, while keeping the diva-
lent charging (30 s), activation (180 s), protein contact
(30 s for all densities) and quenching (180 s) to mini-
mal constant times, allowed us to both standardise the
method and generate sensor surfaces with between
~ 50 and ~ 4000 RU of stabilised protein. Typical sen-
sorgrams, monitored on intermediate (~ 600 RU) and
extremely low (~ 50 RU) density surfaces of covalently
stabilised His-CypA binding to CsA, are shown in
Fig. 1. (A) Ultrapure, monodisperse and highly active protein is used for sensor-surface generation. (A) 4–15% acrylamide SDS Stain-free
TGX gel (BioRad, Hercules, CA, USA) illustrating the final purity of His-CypA (2 lg total protein). Standards are shown to the left. (B) Size-
exclusion chromatography (AKTA-Micro; GE Healthcare) coupled with UV, static light scattering and RI detection (Viscotec SEC-MALS 20
and Viscotek RI Detector:VE3580; Malvern Instruments), were used to determine the molar mass of His-CypA in solution. About 100 lL of
1 mgmL1 His-CypA was run on a Superdex-75 10/300 GL (GE Healthcare) size exclusion column pre-equilibrated in 10 mM NaH2PO4, pH
7.5; 150 mM NaCl at 22 °C, at 0.8 mLmin1. Light scattering, RI and A280 nm were analysed by a homo-polymer model (OMNISEC software, v
5.1; Malvern Instruments) using the following parameters: @A/@c at 280 nm 0.71 AUmL1mg1 and @n/@c of 0.185 mLg1. His-CypA
protein elutes a single sharp peak with a correlative Rs of 1.82  0.1 nm (mean  SEM, n = 5). Elution positions for standards are shown
above the chromatograph. The molar mass average across the elution profile is 19.8 kDa with excellent monodispersity (Mw/Mn = 1.003).
The theoretical molecular weight of His-CypA is 21.04 kDa. DLS analysis (data not shown) also indicates high monodispersity for His-CypA
solutions with a mean Rh of 1.85  0.17 nm (mean  SEM, n = 5), a polydispersity index of ≤ 0.1, and a correlative molecular weight of
between 19 and 21 kDa, consistent with a highly pure and monomeric protein solution. (C) Inhibition of His-CypA’s PPIase activity by CsA.
Initial background corrected reaction (V0) rate in lMs
1 is plotted versus the concentration of CsA in nM. Solid lines are a least squares fit of
the data to Eqn (1) (see Material and methods). Each point is the mean  SE, n = 3. The mean Ki value for CsA, at 12 °C, is
15.03  1.38 nM.
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Fig. 2B,C. The on-rate (k+), off-rate (k) and
equilibrium dissociation constants (Kd) are essentially
identical for both surfaces. Mean values for ka, kd and
Kd at 25 °C, on intermediate density surfaces are
(0.79  0.06) 9 106 M1·s1, 0.018  0.004 s1 and
22.8  3.6 nM (Fig. 2B), respectively, compared to
(0.73  0.07) 9 106 M1·s1, 0.018  0.006 s1 and
24.7  5.3 nM (Fig. 2C), on low-density surfaces. Our
data here are in excellent agreement with the values
for these biophysical parameters determined in solu-
tion studies by isothermal titration calorimetry (ITC)
[20,24,25], fluorescence titration [23,25–27,29], SPR
[25,26], enzymatic analysis [23,26,28,29] and NMR
[21].
Capture via the His-tag, under ‘physiological’ pH
and salt concentration, reduces or eliminates any elec-
trostatic adsorption to carboxmethyldextran matrix,
while orienting the protein away from the sensor sur-
face, and prevents any uncontrolled and spurious cou-
pling reactions that are liable compromise the
coherency of the immobilised protein. The covalent
reaction on these surfaces is therefore focused and
brief, and only occurs proximally to the His-tag; likely
either the N terminus itself or the lysine residue N-
terminal to the hexa-his sequence in the construct.
Similar rationales have been used for making sensor
surfaces with whole cellular receptors [54] and His-
RGS proteins [55]. In our hands, standard covalent
coupling methods have never yielded satisfactory
results for the cyclophilins. As previously discussed
[26], the X-ray structure of CypA [56] shows the
majority of surface exposed lysine residues are located
on the CsA-binding face of the molecule giving it a
predominantly basic character. Under the acidic solu-
tion conditions (even mildly acidic) required for the
standard primary amine immobilisation process, the
surface charge potential of CypA seems likely to force
the molecule to orient with the CsA-binding surface
face-down on the matrix, resulting in severe steric
occlusion of this site for ligand access. A further con-
sideration that contributes to low protein activity when
using direct coupling approaches is an acidic pH shift-
dependent affinity loss that occurs quite rapidly with
CypA. This behaviour has been observed in ITC,
intrinsic fluorescence experiments with CypA and its
ligands [24,26,30]. The reasons and mechanism for this
are not entirely clear, but it involves a combination of
protein protonation and a resultant partial irreversible
denaturation of the protein in solutions with a pH
below ~ 5.5 that quickly leads to irreversible structural
changes and aberrant binding behaviour [24,26,30].
The most effective conditions we have found in our
laboratory so far for direct coupling of CypA are 100–
120 lgmL1 protein in 10 mM acetate buffer, pH 5.8
(the predicted pI of the protein is 6.54), with a 30 s
contact time on an activated CM5 sensor surface. Fig-
ure 2D illustrates the type of data typically generated
from such surfaces. The protein immobilised on these
sensors is very clearly compromised in terms of its bio-
physical state. Longer contact times reduce the already
poor specific activity and anomalous ligand-binding
behaviour further. The specific activity is only around
35% and it decays quite rapidly. Furthermore, the
interaction is clearly not 1 : 1 and has ill-defined mul-
tiphasic kinetics (Fig. 2D). The mean values
(mean  SEM, n = 3) for ka, kd and Kd, at 25 °C,
determined from fitting a 1 : 1 model, for which
the data are clearly not well described, are
(0.48  0.1) 9 106 M1·s1, 0.14  0.1 s1 and
291.7  104 nM respectively. The affinity is 12–14-fold
weaker with significantly altered kinetics; kd is 8–10-
fold faster and the ka twofold slower, compared to the
interaction assessed on surfaces of oriented and sta-
bilised His-CypA (compare Fig. 2B and D). This very
clearly indicates that this is a protein surface that is
far from being biophysically coherent and does not
agree with the data from other solution studies. The
accepted Kd range for the CypA:CsA interaction sits
between 10 and 30 nM, with the variation arising from
slight differences in the buffer systems and their ionic
strength, the pH, the temperature of analysis and the
specific analysis technique used in the particular study
in question [20,21,23–30]. Surfaces of CypA generated
by direct covalent immobilisation should really not
then be utilised in any further experiments as they lack
any rigorous correlative validation from any orthogo-
nal techniques. Regrettably for the cyclophilins, and
especially CypA, there are repeated examples in the lit-
erature where SPR sensor surfaces, all generated by
standard primary amine coupling chemistry and show-
ing very inappropriate and non-native affinities and
kinetics, have been used to screen/assay ligands. There
are instances where such surfaces have been used with-
out any assessment of appropriate activity with a posi-
tive control, others where surfaces are used despite the
affinity for CsA being reported as being orders of
magnitude weaker (10–50-fold) than the normal
expected range, and others still where the apparent
binding affinities of ligands assessed by SPR do not
correlate at all with any other assays employed in the
study [57–60]. This is poor practice and at best, mud-
dies the water for the field.
We next assessed the ability of our His-CypA sur-
faces to produce equilibrium thermodynamic data.
Our streamlined surface generation clearly increased
the coherency and stability of the protein on the
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sensor surfaces, allowing for a significant expansion of
the thermo-kinetic analysis space from 5 °C to 44 °C,
compared to the previous range of ~ 16 °C to ~ 35 °C
[25,26]. The protein on these new surfaces was stable
at temperatures up to 44 °C and could be repeatedly
raised to this temperature without significant loss of
binding activity or deviation in the kinetics. Single-
cycle kinetic experiments with CsA were performed at
Fig. 2. Optimisation of capture/stabilisation parameters on modified nitrilotriacetic acid-sensor surfaces. (A) Graphical representation
comparing the EDC–NHS activation time with the final levels of immobilised His-CypA (white bars, left axis) and the corresponding specific
activity of the surfaces (dark grey bars, right axis). Contact time in each experiment was 30 s with a 100 nM solution of His-CypA. In all
cases the experimental RUmax value was generated by passing 1.2 lM CsA in 10 mM NaH2PO4, pH 7.5, 150 mM NaCl, 50 lM EDTA; 0.05%
surfactant P20; 1% ethanol over the surface. (B) Representative reference corrected SPR sensorgrams (black), monitored on a surface with
612 RU of covalently stabilised His-CypA (100 nM, 30 s of contact following 180 s of activation). A twofold dilution series of CsA, from
500 nM to 1.95 nM, was run at 25 °C in 10 mM NaH2PO4, pH 7.5, 150 mM NaCl, 1 mM EDTA; 0.05% surfactant P20; 1% ethanol at
100 lLmin1. The on- and off-rate constants were by globally fitting (red) a 1 : 1 kinetic binding model to the sensorgrams using the
analysis software (v2.02; GE Healthcare) supplied with the instrument. Mean values (n = 5, SEM) determined for the on-rate (ka), off-rate
(kd) and equilibrium dissociation constants (Kd) are (0.79  0.06) 9 106 M1·s1, 0.018  0.004 s1 and 22.8  3.6 nM respectively. (C)
Reference corrected SPR single-cycle kinetic sensorgrams (black), monitored on a surface with 58 RU of covalently stabilised His-CypA
(10 nM, 30 s of contact following 180 s of activation). A threefold dilution series of CsA, from 200 to 2.46 nM, was run at 25 °C in 10 mM
NaH2PO4, pH 7.5, 150 mM NaCl, 1 mM EDTA; 0.05% surfactant P20; 1% ethanol at 100 lLmin1. The on- and off-rate constants were by
globally fitting (red) a 1 : 1 kinetic binding model to the sensorgrams using the analysis software (v2.02; GE Healthcare) supplied with the
instrument. Mean values (n = 3, SEM) determined for the on-rate (ka), off-rate (kd) and equilibrium dissociation constants (Kd) are
(0.73  0.07) 9 106 M1·s1, 0.018  0.006 s1 and 24.7  5.3 nM respectively. (D) Reference corrected SPR single-cycle kinetic
sensorgrams (black), monitored on a surface with 780 RU of His-CypA immobilised utilising standard amine coupling chemistry
(100 lgmL1 His-CypA in 10 mM acetate, pH 5.8, with a 30-s contact time with the activated surface). A threefold dilution series of CsA,
from 200 to 2.46 nM, was run at 25 °C in 10 mM NaH2PO4, pH 7.5, 150 mM NaCl, 1 mM EDTA; 0.05% surfactant P20; 1% ethanol at
100 lLmin1. The on- and off-rate constants were by globally fitting (red) a 1 : 1 kinetic binding model to the sensorgrams using the
analysis software (v2.02; GE Healthcare) supplied with the instrument. Mean values (n = 3, SEM) determined for the on-rate (ka), off-rate
(kd) and equilibrium dissociation constants (Kd) are (0.48  0.1) 9 106 M1·s1, 0.14  0.1 s1 and 291.7  104 nM respectively.
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temperatures ranging from 5 °C to 44 °C, in 3 °C
increments, with a threefold dilution series of CsA
from 2.45 to 200 nM. Figure 3 shows typical fitted
data from a high-density sensor surface and the ka, kd
and Kd values derived from this analysis shown in
Table 1. This increased sensor surface stability permits
analysis of ligand interactions at physiologically rele-
vant temperatures, critical for proper exploration of
the temperature effects on the affinity and kinetics in
small molecule drug-discovery studies. Additionally,
the increased sensitivity and structural integrity of the
protein surface also allowed us to routinely use lower
concentrations of CsA, eliminating the solubility issues
with CsA (a very hydrophobic molecule), and allowing
extension by over 10 °C of the lower temperature anal-
ysis range.
From 5 °C to 44 °C, the off-rate for CsA is
increased ~ 175-fold compared to a ~ 9-fold increase
in the on-rate (Table 1), resulting in a 23-fold loss of
affinity from ~ 5 to ~ 120 nM (Fig. 4A, Table 1). The
van’t Hoff plot of these data are very clearly nonlinear
(Fig. 4) indicating a change in the heat capacity (DCp)
of the system upon binding. A fit of Eqn (4) to these
data (solid line, Fig. 4) gives the following thermody-
namic parameters at standard temperature (25 °C);
DG° = 10.38  0.21 kcalmol1, DH° = 15.50
 0.8 kcalmol1, TDS° = 5.12  0.5 kcalmol1;
DCp = 0.41  0.16 kcalmol1K1 (Table 1). Nega-
tive DCp values can be correlated with reduced solvent
accessibility for nonpolar surfaces during complex for-
mation. They are often also indicative of conforma-
tional complexity in one or other of the components
of the reaction, with changes in conformation between
free and complexed states being markedly different.
Another important contributor to negative DCp values
is the trapping of water molecules at the binding inter-
face of the complex, often forming or contributing to
a critical feature of the binding interaction surface,
with each water having been calculated to contribute
about – 0.05 kcalmol1K1 to the overall DCp
[24,61]). The heavily enthalpic CypA–CsA interaction
is not only primarily driven by hydrophobic and van
der Waals interactions, but also critically, contacts that
involve five well-defined water molecules trapped at
the binary complex interface [24,61]. This coupled to
the significant entropic cost of complexing a large and
flexible ligand such as CsA (a cyclic undecapeptide
[62]), explains the energetic parameters and the very
obvious negative DCp in relation to the CypA–CsA
complex structure [24,25,61–64].
The thermodynamic parameters determined here
agree exceptionally well with those measured in
Fangh€anel and Fischer’s [24] detailed study of the
CypA–CsA interaction by ITC, performed at 25 °C in
25 mM phosphate buffer at pH 7.5; DG° = 10.69
 0.11 kcalmol1, DH° = 14.7  0.03 kcalmol1,
TDS° = 3.8 kcalmol1; DCp = 0.44  0.007 kcal
mol1K1. The very small disparities arise due to sub-
tle differences in the analysis platforms and varying
contributions from solvation/desolvation effects, buffer
ionisation/proton exchange effects (although essentially
eliminated at pH 7.5) and conformational fluctuations
(free diffusion versus surface immobilised) in the reac-
tants during complex formation. There is now excel-
lent convergence in the DCp values determined from
this SPR study, those determined from rigorous ITC
analysis [24] and those calculated from structure-based
calculations on the CypA:CsA binary complex; all are
essentially ~ 0.4 kcalmol1K1 [24,25,61–64]. The
agreement with solution, and label-free studies, further
supports the view that our His-CypA SPR sensor sur-
faces, and the interaction of ligands with the protein,
are unaffected by the immobilisation process and
behave essentially as they would if free in solution and
are representative of the correct physiological interac-
tion. About 1000 RU of CypA on the surface corre-
sponds to ~ 3 9 1010 protein molecules immobilised
within a volume of ~ 1 9 1014 nm3. This gives an
average intermolecular spacing between each His-
CypA molecule of at least 120 A. 2000 RU gives spac-
ing of ~ 85 A and 3000 RU ~ 50 A. None of these
densities would have surface ‘crowding’ issues, and lit-
tle possibility of heterogeneity arising due to steric
occlusion by neighbouring molecules. This sparse and
stable binding arrangement goes partway to explaining
the excellent agreement in the values for the kinetic
and equilibrium constants from our SPR data, the
other solution techniques.
The BIAcore T200 instrument used in this study is
by far the best platform for analysing such a system,
both in terms of the signal-to-noise limits [baseline
noise limits are < 0.03 RU (RMS), < 0.1 (RMS) and
< 0.33 RU (RMS) for the T200, T100 and 3000 sys-
tems respectively; sourced directly from GE Healthcare
product technical specification data] and the tempera-
ture control for analysis. A note here, the new BIA-
core S200 system has better specifications for baseline
noise, < 0.0015 RU (RMS), but with the same sensitiv-
ity for ligand detection as the T200, but we neither
have access to nor have we tested the system.
The T200 system has an operating temperature
range of 4–45 °C, and will actually achieve the limits
of this range. The T100 has the same stated range lim-
its, but this is heavily dependent on the ambient tem-
perature the instrument is operated in. We know from
experience that the system was able to only practically
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cool to ~ 18 °C below ambient and under standard
laboratory conditions (even though the stated maxi-
mum is 20 °C). The 3000 instrument possesses a man-
ufacturer’s quoted range of 4–40 °C (less than the
other two systems at the top end by 5 °C). Again, this
is even more dependent on the ambient operating tem-
perature the instrument the system is operated in. Our
experience is that this system is able to only practically
cool to ~ 15–16 °C below ambient (even though the
stated maximum is 20 °C, this can only really be
Fig. 3. Effect of temperature on the binding of CsA to His-CypA. Reference corrected SPR single-cycle kinetic sensorgrams (black),
monitored on a surface with 2378 RU of covalently stabilised His-CypA (250 nM, 30-s contact following 180-s activation) for the indicated
CsA concentrations (200–2.46 nM) from 5 °C to 44 °C in 3 °C increments. The on- and off-rate constants were by globally fitting (red) a
1 : 1 kinetic binding model to the sensorgrams using the analysis software (v2.02; GE Healthcare) supplied with the instrument. Mean
values (n = 3, SEM) determined for the on-rate (ka), off-rate (kd) and equilibrium dissociation constants (Kd) are shown in Table 1.
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achieved reliably in environments with ambient tem-
peratures of 18–19 °C). The superior functionality and
sensitivity of the BIAcore T200 and the significantly
increased activity and stability of the protein surfaces
were primary factors in our ability to extend the
thermo-kinetic analysis space reliably.
The thermodynamic parameters generated across
this expanded range by this new method are much
more comprehensive and robust, and there is now a
very good convergence in the energetic parameters for
binding CsA, particularly for the DCp parameter,
between the results reported here and those determined
by ITC and structure-based calculations [24,62], where
buffer systems have been matched. Notably, DCp is
notoriously difficult to determine by noncalorimetric
methods and a critical factor in formulating a com-
plete understanding and rationalisation of the binding
interface and structural features driving molecular
recognition/complex formation; vital for rational
ligand/drug design. This is especially so when using
atomic resolution structures to guide the development
of new ligands.
It is also noteworthy that the buffer system used
here is phosphate-buffered saline compared to
HEPES-buffered saline used previously. The thermo-
dynamic parameters that have been determined by our
lab and others change dependent on the buffer system
used in the analysis. The changes can be small and
sometime subtle, but genuine, and represent differences
in the binding energetics, the interface contacts and
the interactions between the protein and the solvent
and solutes in it. Given the subtlety that clearly exists
in the mechanism of binding for ligands in the active
site of the cyclophilins and that this binding is ‘fi-
nessed’ by the solution conditions, it is important to
have characterisation of the binding in multiple sol-
vents/solution conditions. This allows for a more com-
prehensive understanding of the molecular contacts
Table 1. Temperature dependence of the kinetic and equilibrium affinity constants for CsA binding to recombinant human His-CypA,
determined by BiacoreTM T200.
Temp (°C) Kd (nM) ka (M
1s1) kd (9103 s1)
5 5.5  1.2 (0.22  0.05)9106 1.2  0.08
8 7.1  1.2 (0.27  0.02)9106 1.9  0.2
11 7.6  1.7 (0.33  0.08)9106 2.5  0.1
14 9.6  1.2 (0.42  0.04)9106 4.1  0.2
17 12.2  2.1 (0.47  0.08)9106 5.7  0.2
20 14.3  1.4 (0.59  0.04)9106 8.4  0.4
23 20.4  2.7 (0.61  0.1)9106 12.4  0.6
26 27.6  4.9 (0.67  0.1)9106 18.5  1
29 38.4  8.2 (0.77  0.14)9106 29.5  2.1
32 52  6.1 (0.83  0.09)9106 43.0  1.0
35 75.1  13 (1.1  0.21)9106 83.6  3.4
38 90.1  9.6 (1.3  0.36)9106 118  3.6
41 117  16.6 (1.8  0.41)9106 211  7.8
Temp (°C)
van’t Hoff analysis
DG° (kcalmol1) DH° (kcalmol1) TDS° (kcalmol1) DCp (kcalmol1K1)
25 °C 10.38  0.21 15. 50  0.8 5.12  0.5 0.41  0.16
Kd values (mean  SE, n = 3) were calculated using the formula Kd = kd/ka. van’t Hoff parameters calculated from a fit of Eqn (4) to a plot
of lnKd versus 1/T in K (Fig. 3).
Fig. 4. Thermodynamic characterisation of the CypA–CsA
interaction by SPR BiacoreTM T200. Plot of lnKd versus 1/T in K.
Data were fit (solid line) to Eqn (4) using KALEIDAGRAPH v4.1.3
software (Synergy Software). Thermodynamic parameters
calculated from these data are shown in Table 1.
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and how solution changes are likely to alter the inter-
action between the protein and the ligand. For exam-
ple, the relatively small energetic changes that arise
from trapping water molecules at the binding interface
(~ 0.05 kcalmol1K1 per trapped water) and/or
the conformational subtlety in the contacts with this
pseudo binding interface and ligands could potentially
add up to 10 s of nM difference in affinity, contributed
from DCp alone. In addition to these differences in the
binding energetics/molecular contacts, understanding
these solution differences potentially allows for speci-
ficity to be built into future ligand development by
exploiting the differences in the way isoforms and the
protein–ligand complexes interact with the solvent. To
do this efficiently and rationally, we feel it is crucial to
characterise the interaction as fully as possible, in
multiple solution environments that maintain physio-
logical relevance.
The cyclophilins are validated drug targets for a
number of diseases including HIV and HBV infection,
malaria, recovery from ischemia, parasitic worm infec-
tion, immunosuppression and numerous proliferative
cancers [23,31–45]. Our laboratory is particularly inter-
ested in finding new compounds and analogues that
could provide new chemical scaffolds for the synthesis
of families of peptidomimetic molecules with potential
isoform-specific inhibitory activity against these viral
and parasite infections. Screening fragment (molecular
weights in the 100–250 Da range) libraries, either by
high-throughput X-ray crystallography, NMR or SPR
has been established as a rationale that allows rapid
and effective interrogation of key binding interactions
Fig. 5. Binding and structural analysis of His-CypA–2,3-diaminopyridine complex. (A) Reference corrected SPR single-cycle kinetic
sensorgrams (black), monitored on a surface with 2866 RU of covalently stabilised His-CypA (300 nM, 30-s contact following 180-s
activation) for the indicated 2,3-diaminopyridine concentrations (1 mM–62.5 lM). The apparent equilibrium dissociation was determined by
fitting (red) a 1 : 1 Langmuir binding model (inset) to the sensorgrams using the analysis software (v2.02; GE Healthcare) supplied with the
instrument. The mean Kd value is 248  60 lM (n = 3, SEM). (B) Electrostatic surface of the structure of CypA in complex with 2,3-
diaminopyridine (PDB: 5LUD). The ligand is drawn with purple carbons and is observed in the Abu pocket, the hydrophobic active site is
below in the orientation shown. (C) Electron density and 2,3-diaminopyridine–CypA interaction details. The omit electron density (Fo  Fc)
contoured at 3r is shown around the 2,3-diaminopyridine ligand as a green mesh, all ligand atoms are clearly defined in density. Direct
hydrogen bond interactions to the ligand are represented as yellow dashes, while bridged water–protein hydrogen bonds are represented as
black dashes. (D) Comparison of the CypA–2,3-diaminopyridine structure (grey carbons – protein, purple carbons – ligand) and the CypD–
ligand structure of 4J5C (Cyan carbons – protein, Green carbons – ligand). Comparitive distances in the respective complexes are indicated
(yellow dashes/black labels, CypA–2,3-diaminopyridine; red dashes/red labels CypD–ligand structure 4J5C).
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on the protein, reproducibly and specifically [65–67].
Even though a fragment’s intrinsic potency is often
very weak (Kd or IC50 values are typically in the high
100 s of lM to mM ranges), the advantage is that they
are small enough to minimise the chances of unfavour-
able molecular contacts that would prevent them from
binding efficiently. This allows fragment libraries to be
constructed to sample a large chemical diversity or tar-
get-specific interactions on the protein. To this end we
screened The Scottish Hit Discovery Facility (Univer-
sity of Dundee) fragment library on a surface of His-
CypA created by our capture/stabilisation method.
This fragment library represents a set (670 compounds)
of diverse structures that comply with Astex’s ‘Rule of
Three’ [65], have excellent medicinal chemistry
tractability and feature as key pharmacophores in a
large number of bioactives.
All the fragments were initially screened at 1 mM on
a high-density (to account for the mass ratio of the
fragments to His-CypA) surface of 2866 RU cova-
lently stabilised His-CypA- and cyclophilin-A-specific
hits were further analysed with a twofold concentra-
tion series from 0.0625 to 1 mM (see Material and
methods). We identified a fragment, 2,3-diaminopyri-
dine that bound specifically and stoichiometrically to
CypA. Typical sensorgrams showing the binding of
this fragment to His-CypA are shown in Fig. 5A with
an average Kd of 248  60 lM. We also solved the X-
ray structure of this fragment bound to CypA to a res-
olution of 1.25 A (PDB ID: 5LUD; Fig. 5B–D;
Table 2). As expected, the overall structure of CypA
(Fig. 5B,C) shows no major differences between the
available apo- and ligand-bound structures of CypA
(PDB IDs 2CPL and 4N1M respectively). Electron
density is present for only one copy of the ligand
bound to the cyclophilin molecule (Fig. 5C) in agree-
ment with the stoichiometric binding determined from
our SPR analysis (Fig. 5A). The ligand is found bound
within the small cleft, adjacent to the hydrophobic
active site, commonly referred to as the Abu pocket
(Fig. 5B). The electron density for the ligand is excel-
lent, with all of its atoms well defined allowing the
unambiguous positioning of the ligand in the binding
cleft (Fig. 5C). The pyridine ring is sandwiched in the
cleft formed by the main-chains of alanine-101 and
asparagine-102 on one side, and the carbonyl of gly-
cine-72 and the side-chain of glutamine-111 on the
other. Only weak interactions are observed around the
pyridine ring. Both amino groups point towards the
back of the Abu pocket and somewhat surprisingly,
only a single one – the 3-amino group – interacts
directly with the protein; the 2-amino group forms a
long range (3.31 A) hydrogen bond to the carbonyl of
threonine-107 (Fig. 5C). The strongest interactions
that the ligand makes are to three water molecules (la-
belled w1 to w3; Fig. 5C). These water molecules
bridge interaction between the protein surface and the
ligand. The 3-amino group forms a hydrogen bond to
a single water molecule (w3) which in turn bridges to
the carbonyl of Threonine-73 (Fig. 5C), while the 2-
amino group forms hydrogen bonds to two water
molecules (w1 and w2; Fig. 5C). These are very well
defined with each having a low B-factor (17.64 and
17.67 A2, for w1 and w2 respectively) and are reported
as being well conserved in a number of cyclophilin
structures [15,68]. They form an integral part of the
interaction surface of the binding site of cyclophilins.
Each of these water molecules further form three
hydrogen bonds with the protein; w1 bonding to the
main-chain carbonyls of threonine-107, glutamine-111
and the main-chain NH of glycine-107 (Fig. 5C). w2
forms hydrogen bonds to the carbonyl of Glycine-74
and the main-chain NHs of serine-110 and glutamine-
111 (Fig. 5C). The role of these well-defined bridging
water molecules reiterates that targeting water mole-
cules rather than replacing them may in some case
enhance or finesse the binding specificity and be
preferable in considerations for ligand design [69,70].
Recently, a number of structures of submicromolar
nonpeptide inhibitors of cyclophilin-D (CypD), with
evidence of inhibitory interactions with CypA, have
been reported containing an aniline group bound
within the Abu pocket [71]. Overlaying our CypA: 2,3-
Table 2. X-ray data collection and refinement statistics.
X-ray source I02 (DLS)
Wavelength (A) 0.97949
Space group P212121
Unit cell (A) a = 42.53, b = 54.48, c = 86.81
Resolution range (A) 33.95–1.25 (1.27–1.25)
Total observations 203 449
Unique reflectionsa 55 267 (2453)
Redundancy 3.7 (2.7)
I/r(I)a 8.7 (1.0)
Rmerge (%)
a 6.5 (59.4)
Completeness (%)a 97.8 (89.5)
Refinement statistics
Resolution limit (A)a 33.0–1.25 (1.28–1.25)
R-factor (%) 19.3 (31.4)
Rfree (%) 21.9 (32.2)
No. of protein atoms 1303
No. of water atoms 238
No. of ligand atoms 8
RMSD bond lengths (A) 0.0254
RMSD bond angles (°) 2.294
Mean B factor (A2) 17.751
aValues in parentheses refer to the highest resolution shell.
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diaminopyridine structure reported here and the crys-
tal structure of CypD in complex with one of these
inhibitors (PDB ID: 4J5C) reveals a very close correla-
tion between the aniline and the equivalent atoms of
the 2,3-diaminopyridine (the mean distance for seven
equivalent atoms is 0.31, RMSD for 164 C-alpha pro-
tein atoms is 0.437, Fig. 5D). It is noticeable that the
amine group in the 4J5C structure does not have as
tight an interaction to the equivalent w1 water mole-
cule, compared to 2,3-diaminopyridine; the distance of
the equivalent bond increasing by 0.34 to 3.53 A. The
amine group in the CypD structure is near equidistant
between this water and the side-chain of arginine-124.
The equivalent side-chain in CypA is lysine-82, and
this residue side-chain adopts a different conformation
that does not interact with the 2,3-diaminopyridine
ligand (Fig. 5D). This important difference provides a
tantalising indication towards a route to isoform-speci-
fic ligand design for CypA.
The structure of cyclophilin-A in complex with
2,3-diaminopyridine also validates our refined
methodology for generating SPR sensor surfaces of
recombinant his-tagged human cyclophilin-A. Fur-
thermore, it highlights the potential role of bridging
water molecules in ligand design and may provide
insight for the future design of isoform-specific cyclo-
philin inhibitors.
The new protocols reported here have very signifi-
cantly, and rationally, optimised the basic methodol-
ogy previously developed in our lab. This major
protocol refinement has allowed for advancement in
the biophysical characterisation of the protein and
ligand binding interaction, and importantly, identifica-
tion of a new nonpeptide hit/ligand for CypA. The
improved activity and stability of the material on the
surface of the sensors, and the ability to use much
lower concentrations of a complicated ligand with sol-
ubility issues (CsA), as a direct result of this increased
sensitivity and activity, allowed the measurement of
the binding interaction over a much wider temperature
range, than has been possible before. We were able to
expand the thermo-kinetic range by 10 °C in both
directions in this new work – from 16–35 °C to 5–
44 °C. This also enabled us to increase the data den-
sity across this expanded temperature range by a fac-
tor of nearly 3 (14 sets of kinetic measurements versus
5); resulting in a much more robust kinetic, affinity
and thermodynamic characterisation of the binding
interaction between CypA and CsA. Of note, the work
presented here is the most comprehensive study of
Cyp–CsA interaction by SPR to date, and was only
achievable by the developments in methodology devel-
oped by our lab and described here.
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